Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Grenoble – page 6

663 clinical trials in Grenoble, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Grenoble at a glance
663
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

663 trials in Grenoble

Open in trial search

Follicle centre lymphoma follicular grade I, II - III

Recruiting

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic obstructive pulmonary disease

Recruiting

Long-term Safety Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease and History of Exacerbations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatocellular carcinoma

Recruiting

A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:CatalYm GmbH

Renal transplant

Recruiting

A Study of Felzartamab for Kidney Transplant Patients with Late Isolated Microvascular Inflammation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

Non-small cell lung cancer

Recruiting

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer stage IV

Recruiting

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Grenoble

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck cancers, multiple myeloma, and various types of leukemia. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Advanced NSCLC Treatment Studies
  • Gastric Cancer Immunotherapy
  • Hematologic Malignancies

Innovative approaches combining immunotherapy with standard treatments are showing promise in treating various forms of cancer.

02 Transplant Medicine

Clinical investigations examining kidney transplant outcomes and rejection prevention. Research focuses on new therapeutic approaches for managing transplant-related complications.

  • Antibody-Mediated Rejection
  • Novel Immunosuppression Strategies
  • Long-term Graft Survival

Studies aim to improve transplant success rates and reduce rejection incidents through innovative medication protocols.

03 Neurological Disorders

Research into narcolepsy and multiple sclerosis treatments, evaluating new therapeutic approaches for better symptom management and disease control.

  • Sleep Disorder Management
  • MS Treatment Innovations
  • Neurological Disease Progression

Cutting-edge treatments being developed to address both rare and common neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.